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Abstract
Background: Inorganic mercury (Hg) induces a T-cell dependent, systemic autoimmune condition (HgIA) where activating
Fcc-receptors (FccRs) are important for the induction. In this study we examined the influence of activating FccRs on
circulating levels and organ localization of immune complexes (IC) in HgIA.
Methods and Principal Findings: Mercury treated BALB/c wt mice showed a significant but modest increase of circulating
IC (CIC) from day 12 until day 18 and day 35 for IgG2a- and IgG1- CIC, respectively. Mercury-treated mice lacking the trans-
membrane c-chain of activating FccRs (FcRc
2/2) had significantly higher CIC levels of both IgG1-CIC and IgG2a-CIC than wt
mice during the treatment course. The hepatic uptake of preformed CIC was significantly more efficient in wt mice
compared to FccR
2/2 mice, but also development of extrahepatic tissue IC deposits was delayed in FcRc
2/2 mice. After 35
days of Hg treatment the proportion of immune deposits, as well as the amounts was significantly reduced in vessel FcRc
2/2
mice compared to wt mice.
Conclusions: We conclude that mice lacking functional activating FccRs respond to Hg with increased levels and altered
quality of CIC compared with wt mice. Lack of functional activating FccRs delayed the elimination of CIC, but also
significantly reduced extrahepatic tissue localization of CIC.
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Introduction
The deposits of glomerular immune complexes (IC) is a
hallmark of certain systemic autoimmune diseases with glomeru-
lonephritis (GN) [1]. However, the formation of ICs is also a
physiological function of the immune system in order to eliminate
antigens and to regulate immune responses [2,3] . IgG-containing
circulating ICs (CIC) are cleared via Fc-gamma receptor (FccR)
dependent uptake by Kupffer cells as well as liver sinusoidal
endothelial cells [4–8]. In addition, hepatic elimination and
extrahepatic deposition of CIC are affected by complement and
complement receptors [9,10]. If the physiological mechanisms of
hepatic IC-elimination fails, extrahepatic tissue deposition of IC
may occur and lead to tissue inflammation and organ damage [1].
The damage following tissue IC deposits depends on the
mechanism and site of formation, but especially on the amount
of deposits and their composition [1]. Thus, tissue ICs in systemic
inflammatory disease may be derived from the circulation, as
indicated by murine autoimmune models [11,12], and in human
diffuse proliferative lupus nephritis [13], or membranous GN [14].
The amount of CIC correlates with disease severity in systemic
lupus erythematosus (SLE), where patients with overt nephritis
show higher levels of CIC than patients with silent nephritis
[15,16]. Tissue IC deposits may, however, also form in situ, either
by the interaction of antibodies (abs) with antigens planted in the
glomerulus, or by binding of abs to intrinsic glomerular antigens
[17,18]. Formation of tissue IC deposits in SLE may be due to
abnormal handling by FccRs since hepatic FccR-mediated IC
clearance is less efficient in SLE patients than in healthy
individuals [19].
All murine FccRs ligate exposed Fcc parts of ICs via the
surface-exposed c-chain: FccRI, FccRIII and FccRVI, but not the
inhibitory FccRIIb, then promote cell activation via a signal-
transducing trans-membrane dimeric c-chain (FcRc) residing the
immune receptor tyrosine-based activation motif (ITAM) [20].
Furthermore, the trans-membrane FcRc is essential for endocy-
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opsonized particles via the stimulating FccRs, although Fc-ligation
remains intact [20,21]. FccRIII is the predominant receptor in
triggering immune effector functions following murine IgG1-IC
binding [22]. The response is also influenced by the inhibitory
FccRIIb, where the immune receptor tyrosine-based inhibitory
motif (ITIM) becomes phosphorylated upon Fc-ligation, thereby
inhibiting ITAM- signalling [20]. In rats, the FccRIIb2 of liver
sinusoidal endothelial cells (LSEC) is used not only as a receptor
for efficient CIC clearance, but also as a recycling receptor with or
without ligated ICs [8].
Lack of FccRIIB increases the incidence of nephritis in murine
pristane-induced lupus [23], and may even cause spontaneous GN
in some mouse strains [24]. A delicate balance between activating
and inhibitory signals emanating from the FccRs characterizes a
normal immune response. This balance may be disturbed in
autoimmune diseases [2,3,25].
The importance of the activating FccRs (FccRI, FccRIII and
FccRIV in mice) and the inhibiting FccRIIb in autoimmune
diseases has been elucidated in mouse strains with targeted
knockout mutations for these FccRs [25,26]. We have previously
used FccR-deficient mice to explore the role of these receptors in
HgIA [27,28], a model characterized by Hg-induced lymphopro-
liferation, hypergammaglobulinaemia, antinucleolar autoantibod-
ies (ANoA) and IC deposits in the renal glomerular mesangium
and systemically in vessel walls in susceptible mouse strains [29]. In
HgIA, activating FccRs affect development of ANoA [28] as well
as IC deposits [27], while the inhibiting FccRIIb down-regulates
the hyper-gammaglobulinaemic response [27,28].
In this study we aimed at elucidating the effect of the signal-
transducing trans-membrane dimeric c-chain of activating FccRs
in HgIA on levels of CIC, hepatic IC uptake, and the development
and composition of IC deposits in typical target organs in systemic
autoimmune disease.
Results
Firstly, we compare the levels of CIC in wildtype (wt) and
FcRc
2/2 BALB/c mice in relation to the development of tissue IC
deposits during five weeks of Hg treatment. Secondly, we report
differences regarding blood clearance and hepatic uptake of
preformed model immune complexes in the two BALB/c strains.
Thirdly, we analyse the composition of tissue IC deposits in the
two mouse strains after five weeks of Hg treatment.
Increased levels of IgG1- and IgG2a-containing CIC are
associated with development of high-titred tissue IC
deposits in wt BALB/c mice but not in FcRc
2/2 mice
Wt mice. BALB/c wt mice treated with Hg had significantly
higher concentrations of CIC containing IgG1 (Figure 1A) and
IgG2a (Figure 2) after 12 (p,0.001) and 18 (p,0.001) days of
treatment, and regarding IgG1-CIC after 26 (p,0.001) and 35
(p,0.001) days as compared to untreated mice. Renal mesangial
(Figure 1B) and splenic vessel wall (Figure 1C) IgG1 deposits were
first seen after 16 days of Hg treatment, and the fraction of mice
with IC deposits and/or the titre of the deposits increased until
end of treatment after 35 days. Despite the increase of IgG2a-CIC
in Hg-treated wt mice (Figure 2) neither renal mesangial nor
splenic vessel wall deposits contained IgG2a (data not shown).
While C3c deposits were seen already after 12 days treatment in
the renal mesangium, C3c deposits were not seen in splenic vessel
walls until the end of treatment after 35 days of Hg treatment (data
not shown). None of the untreated wt mice showed IgG1, IgG2a
or C3c deposits in glomeruli or vessel walls at any time during the
35 days of Hg treatment (data not shown).
FcRc
2/2 mice. In FcRc
2/2 mice the levels of IgG1-
containing CIC were highest after 12 days of Hg treatment
(Figure 1A), but remained significantly increased compared to
untreated FcRc
2/2 mice during an additional 14 days of
treatment (for 12 days p,0.01, 18 days p,0.001 and 26 days
p,0.01). The IgG1-CIC level was significantly higher in Hg-
treated FcRc
2/2 mice as compared to wt mice during all of the 35
days (12 days p,0.001, 18 days p,0.001, 26 days p,0.01 and 35
days p,0.05). In the FcRc
2/2 mice, traces of renal mesangial
(Figure 1B) and splenic vessel wall (Figure 1C) IgG1 deposits were
seen after 12–18 days of Hg treatment, but higher titres of IgG1
deposits were not seen until 26 days of treatment (Figure 1B–C).
After 18 days of Hg treatment the titre of IgG1 deposits in the
renal mesangium of FcRc
2/2 mice was significantly lower than in
wt mice (p,0.05).
The level of IgG2a-containing CIC was significantly increased
in FcRc
2/2 mice after 26 and 35 days of Hg treatment compared
to both untreated FcRc
2/2 mice (p,0.001) and Hg-treated wt
mice (26 days p,0.01 and 35 days p,0.05, respectively) (Figure 2).
However, IgG2a deposits were not detected in renal mesangium
or splenic vessel walls at any time (data not shown). C3c deposits
first appeared in the renal mesangium of Hg-treated FcRc
2/2
mice after 12 days but with significantly lower titres than in wt
mice (p,0.05) (data not shown). C3c deposits were seen in splenic
vessel wall of Hg-treated FcRc
2/2 mice after 26 days, and the
fraction of positive mice was significantly higher (p,0.05) than in
Hg-treated wt mice. However, the amount of deposits was low
with a score of 0.560.7 (mean 6 SD). None of the untreated
FcRc
2/2 mice developed IgG1, IgG2a or C3c deposits (data not
shown).
The levels of C1q-binding CIC were measured in the above sera
but there was no difference, neither between Hg-treated and
untreated mice nor between wt and FcRc
2/2 mice (data not
shown).
In conclusion, increased levels of IgG1- and IgG2a-containing
CIC were associated with development of tissue IC deposits in Hg-
treated wt BALB/c mice. While significantly higher levels of CIC
were seen in FcRc
2/2 mice, the development of high-titred tissue
IC deposits was delayed as compared to wt mice.
Intact functional activating FccRs are important for the
elimination of CIC by the liver
BALB/c wt and FcRc
2/2 mice treated with Hg for 15–17 days
showed a similar clearance rate of preformed dinitrophenyl
(DNP)- conjugated human serum albumin (HSA)/IgG IC. No
difference was seen in clearance rate comparing Hg-treated and
untreated mice (data not shown). In contrast, Hg-treated wt mice
showed a significantly higher hepatic uptake of DNP-HSA/IgG
IC compared to Hg-treated FcRc
2/2 mice (p,0.05) demonstrat-
ing the importance of intact functional activating FccRs for the
elimination of CIC by the liver (Figure 3).
Lack of intact functional activating FccRs reduces tissue
IC deposits
Splenic vessel wall IC deposits in wt mice. All nine wt
mice showed IgG1-IC deposits in splenic vessel walls (Figure 4A)
after 5 weeks of Hg treatment, while none of the untreated mice
(p,0.001) showed such deposits (Table 1). Hg treatment caused
slight deposits of IgG2b and IgG3 in one and two mice,
respectively. The proportion of mice with C3c deposits in the
splenic vessel walls was significantly higher (p,0.001) in Hg-
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showed C1q deposits (Table 1).
Splenic vessel wall IC deposits in FcRc
2/2 mice. Eight
out of 9 (89%) Hg-treated FcRc
2/2 mice had developed IgG1
deposits in the splenic vessel walls after 5 weeks (Figure 4B), which
was significantly higher than in the untreated FcRc
2/2 mice
(p,0.001) (Table 1). The amount of IgG1 deposits was
significantly (p,0.05) lower in Hg-treated FcRc
2/2 compared to
Hg-treated wt mice (Table 1). Fifty-six percent of the Hg-treated
FcRc
2/2 mice showed C3c deposits in the splenic vessel walls,
which was significantly higher than in untreated mice (p,0.05).
However, the percentage of mice with C3c deposits as well as the
amount of deposits (p,0.05, p,0.001, respectively) were
significantly lower in Hg-treated FcRc
2/2 mice than in wt mice
(Table 1). None of the untreated FcRc
2/2 mice developed C3c
deposits. Neither Hg-treated nor untreated FcRc
2/2 mice showed
C1q deposits in the splenic vessel walls (Table 1).
Renal glomerular and vessel wall IC deposits in wt
mice. After 5 weeks of Hg treatment renal mesangial IC
deposits were dominated by IgG1 (Figure 4C), although most mice
also showed a relatively low titre of IgG2b. IgG2a and IgG3
deposits were less frequent and of a low titre (Table 2). IgG1 and
IgG2a deposits were not observed in untreated mice. The Hg-
treated wt mice developed mesangial C3c deposits, which were
present also in untreated mice but with only a low titre. None of
the wt mice developed C1q deposits (Table 2).
A single wt mouse treated with Hg but none of the untreated wt
mice showed IC deposits of the IgG1 isotype in the renal vessel
walls (Table 2). Neither Hg-treated nor untreated wt mice
developed C1q or C3c renal vessel wall IC deposits.
Renal glomerular and vessel wall IC in FcRc
2/2
mice. The Hg-treated FcRc
2/2 mice also developed renal
mesangial IC deposits mainly containing IgG1 and IgG2b
(Table 2). The IgG1 titre was significantly lower in Hg-treated
FcRc
2/2 mice than in Hg-treated wt mice (Figure 4D) (p,0.05)
(Table 2). There was no significant difference in the titre of C3c
Figure 2. Development of circulating IgG2a immune complexes. Development of PEG-precipitated circulating IgG2a-containing immune
complexes during 26–35 days of treatment of female BALB/c wild type and FcRc
2/2 mice with 15 mg/L HgCl2 in the drinking water or drinking water
without any addition of Hg (controls). The bars denote mean 6 SD. * p,0.05, ** p,0.01 and *** p,0.001 (Mann-Whitney’s test).
doi:10.1371/journal.pone.0013413.g002
Figure 3. Uptake of circulating immune complexes in the liver.
Uptake of preformed circulating HSA/DNP-IgG immune complexes in
the liver of female BALB/c wild type and FcRc
2/2 mice following 15–17
days of treatment with 15 mg/L HgCl2 in the drinking water or drinking
water without any addition of Hg (controls). The bars denote mean 6
SD. * p,0.05 (Mann-Whitney’s test).
doi:10.1371/journal.pone.0013413.g003
Figure 1. Development of circulating IgG1 immune complexes and tissue IgG1 immune complex deposits. Development of circulating
IgG1-containing immune complexes and tissue IgG1 immune complex deposits during 26–35 days of treatment of female BALB/c wild type and
FcRc
2/2 mice with 15 mg/L HgCl2 in the drinking water or drinking water without any addition of Hg (controls). (A) PEG-precipitated circulating
immune complexes containing IgG1 antibodies. The bars denote mean 6 SD. ** p,0.01 and *** p,0.001 (Mann-Whitney’s test). (B) Renal mesangial
IgG1 and (C) splenic vessel wall IgG1 deposits. Each symbol represents a single mouse. *p ,0.05 (Mann-Whitney’s test).
doi:10.1371/journal.pone.0013413.g001
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from female BALB/c wild type (A, C) and FcRc
2/2 (B, D) mice treated with 15 mg/l HgCl2 in the drinking water for 5 weeks. Heavy granular staining in
splenic vessel walls (A) and renal mesangium (C) in wild type mice, but only slight deposits in the corresponding tissues of FcRc
2/2 mice (B, D).
doi:10.1371/journal.pone.0013413.g004
Table 1. Composition of immune complex deposits in splenic vessel walls from HgCl2-treated and untreated BALB/c mice after 5
weeks.
Splenic vessel walls
Strain No Treatment IgG1 IgG2a IgG2b IgG3 Total IgG C1q C3c
Wt 9 Hg
a 100
b, c 0 11 22 100 0 100
c
(3.160.8)
d (0.160.3) (0.260.4) (2.160.6)
Wt 10 Untreated 0 0 ND ND 0 0 0
FcRc
2/2 9H g
a 89
e 001 1 8 9 0 5 6
f,g
(1.761.1)
h (0.160.2) (0.360.4)
i
FcRc
2/2 10 Untreated 0 0 ND ND 0 0 0
a15 mg/L HgCl2 in the drinking water,
bFraction of mice with immune complex deposits,
csignificantly different from untreated wt mice (Fisher’s exact test p,0.001),
dGrading, 0–4: figures denote mean 6 SD,
esignificantly different from untreated FcRc
2/2 mice (Fisher’s exact test p,0.001),
fsignificantly different from untreated FcRc
2/2 mice (Fisher’s exact test p,0.05),
gsignificantly different from Hg-treated wt mice (Fisher’s exact test p,0.05),
hsignificantly different from Hg-treated wt mice (Mann-Whitney’s test p,0.05),
isignificantly different from Hg-treated wt mice (Mann-Whitney’s test p,0.001)
Wt, wild type mice; ND, not determined.
doi:10.1371/journal.pone.0013413.t001
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2/2 mice and
none of the mice developed C1q deposits (Table 2). Two FcRc
2/2
mice treated with Hg developed IgG1 renal vessel wall deposits
without C1q or C3c deposits (Table 2), whereas none of the
untreated FcRc
2/2 mice showed IgG1, IgG2a, C1q or C3c
deposits.
Taken together these results show that FcRc
2/2 mice develop
less IgG1 and C3c deposits in the splenic vessel walls and lower
IgG1 titre in the renal mesangiumcompared to Hg-treated wt mice.
Discussion
The present study demonstrates that BALB/c mice with Hg-
induced systemic autoimmunity respond with significantly in-
creased concentrations of CIC containing IgG1 and IgG2a
compared to untreated mice. Confirming previous results [12]
we conclude that Hg treatment per se does not affect the
elimination rate of CIC, suggesting that Hg-induced IC formation
accounts for the raised levels of CIC. We also demonstrated that
the concentration of IgG-CIC was significantly higher in FcRc
2/2
mice than in wt animals, and that this functional deficiency in
trans-membrane signalling of activating FccRs is associated with
deficient hepatic clearance of circulating IgG-IC. This accords
with the findings of Ahmed et al, who reported that reduced FccR
expression on hepatic non-parenchymal cells was associated with
spontaneous development of IC-mediated-GN in NZB/WF1 mice
[30]. In SLE reduced expression of FccRIII and FccRII is
association with high levels of CIC, prolonged FccR-mediated
clearance and high disease activity [31]. Willocks et al reported that
a low copy number of the human FCGR3B gene correlates with
reduced neutrophil expression of FccRIIIB as well as with reduced
neutrophil adherence to and uptake of IC in SLE patients [32].
The levels of circulating IgG and IgG-containing IC depend on
several factors e.g. (i) the rate of antibody production, which in turn
depend on the balance between exposure of activating/inhibiting
FccRs [2,3], (ii) elimination from the circulation via non-specific
escape/tissue deposits [10], and (iii) FccR-mediated binding and
endocytosis or recirculation [3–5,8]. It is likely that the increased
CIC concentration in the Hg-treated FcRc
2/2 mice as compared
to wt mice is caused by a disturbance of the normal hepatic IC
clearance. The uptake of CIC was not completely lost in mice
deficient for trans-membrane signalling by activating FccRs. This
may to some extent be explained by IC-adherence to the
stimulating FccRs although endocytosis was deficient, and to
some extend by binding to and endocytosis via FccRIIB2 exposed
on liver sinuoisdal endothelial cells as shown in rats [8].
The profile of CIC increase in Hg-treated mice was quite
different between wt and FcRc
2/2 mice, the former showing a
modest but steady increase from day 12, while the latter showed an
initially 4-fold higher concentrations of IgG1-CIC on day 12
which subsequently declined but with a vigorous increase of
IgG2a-CIC on day 26–35. FcRc
2/2 mice did not respond with a
rise of serum IgG1 following Hg treatment as seen in wt mice
[27,28] indicating another mechanism for the elevation of CIC
levels. The higher and also more variable CIC levels in the Hg-
treated FcRc
2/2 mice might be due both to the reduced ability by
these mice to handle normal levels of CIC and to the extensive
Hg-induced IC-production. The higher concentration of CIC of
first IgG1 and then IgG2a in Hg-treated FcRc
2/2 mice was
associated with a delayed and reduced deposition of IgG1 IC in
the renal mesangium as well as IgG1 and C3c systemically in
vessel walls.
IC deposits can be generated from preformed CIC or by in situ
formation due to adsorption of circulating abs to antigen exposed
in the tissue [11,12,18]. The immune deposits seen in Hg-treated
wt BALB/c mice may thus originated from serum IgG binding
either to antigen planted in the tissue or to endogenouse tissue
antigen, or from tissue deposition/binding of IgG-containing CIC.
There are observations indicating that formation of IC, containing
nucleosomes as antigens, take place within the kidney or in the
circulation prior to deposition [33–35]. The only identified
autoantigen in HgIA is fibrillarin (AFA) [36], which has also been
indicated to be present in murine IC deposits [37]. However, the
presence of AFA is not necessarily followed by IC formation
Table 2. Composition of immune complex deposits in renal mesangial and vessel walls from HgCl2-treated and untreated BALB/c
mice after 5 weeks.
Renal mesangial IC deposits Renal vessel wall IC deposits
Strain No Treatment IgG1 IgG2a IgG2b IgG3
Total
IgG C1q C3c IgG1 IgG2a IgG2b IgG3 C3c C1q
Wt 9 Hg
a 100
b 22 89 67 100 0 100 11 0 0 0 0 0
(13516747)
c (13628) (1696123) (44637) (3916198) (0.160.3)
d
10 Untreated 0 0 ND ND 0 0 100 0 0 ND ND 0 0
(8060)
FcRc
2/2 9H g
a 100
e 25
e 88
e 13
e 100 0 100
f 25 0 0 0 0 0
(6206470)
g (20637) (2006113) (10628) (3896242) (0.461)
10 Untreated 0 0 ND ND 0 0 100 0 0 ND ND 0 0
(176651)
a15 mg/L HgCl2 in the drinking water,
bFraction of mice with immune complex deposits,
cReciprocal titre, figures denote mean 6 SD,
dGrading, 0–4, figures denote mean 6 SD,
eresults from 8 mice,
fresults from 7 mice,
gsignificantly different from Hg-treated wt mice (Mann-Whitney’s test p,0.05).
Wt, wild type mice; ND, not determined.
doi:10.1371/journal.pone.0013413.t002
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formation of AFA as seen in Hg-treated BALB/c mice [27,40].
Anti-nuclear abs (ANA), especially anti-nucelosomal have been
implicated to be important in lupus nephritis [33–35]. Although
anti-nucleosomal abs are seldom induced by Hg treatment of
BALB/c mice, we have previously reported that ANA of IgG1 and
IgG2a subclass is common, indicating antigen-specific induction
[27]. Although the antigen has not yet been identified the typical
ANA pattern in sera from Hg-treated BALB/c mice is fine-
speckled with a distinct staining of nuclear membrane and of
condensed chromosomes in dividing cells [27].
Mesangial cells express FccRs and may mediate binding of IC
by recognition of exposed Fc-part [41]. The loss of functionally
activating FccRs will hinder this particular mechanism of
deposition as shown in the present study as well as in experimental
autoimmune myasthenia gravis. FccRIII deficient mice show
reduction of immune deposits in neuromuscular junctions [42]. An
additional consequence of lost FccRs function is retarded CIC
clearance [31,32] leading to further accumulation of CIC in the
circulation as seen in the present study.
In glomerular diseases IgG-IC may cause tissue damage due to
FccR activation as well as complement activation [43]. In an
experimental model of IC-mediated disease induced by intrave-
nous injection of soluble IgG-IC, Stokol et al showed that the
damaging effect of IC deposits was primarily dependent on C1q,
followed by neutrophil recruitment [44]. The effect of renal
mesangial and systemic vascular IC deposits in Hg-treated BALB/
c mice is a mild glomerular endocapillary cell proliferation and
slight widening of the mesangium, neither of which is affected by
the loss of activating FccRs, or by vasculitis [27]. How might this
mild histological reaction be explained? The frequencies and/or
the amounts of the strongly complement-activating IgG2b, IgG3,
and especially IgG2a antibodies [45] are low in the IC deposits of
HgIA. Instead the IgG1 isotype, which does not activate
complement via the classical pathway, dominates [27] as shown
also by the lack of C1q in the deposits (present study). Another
explanation for the mild renal reaction in HgIA might be that the
glomerular IC deposits in HgIA are strictly localised to the
mesangium [46], which leads to less histological damage [47]. In
fact, when the spontaneously developing glomerular IC-deposits of
NZB/WF1 mice, preferentially situated in the capillary loops, are
relocalised to the mesangium, the histological damage is greatly
reduced [48]. IgG-Fc modulation by in vivo administration of
endoglycosidase-S is a novel and fascinating possibility to treat
autoantibody-/IC-mediated diseases [49]. In the future, other
strategies to specifically interfere with FccR-mediated IC handling
may also become options to treat IC-mediated disease.
In conclusion, mice deficient regarding the function of
activating FccRs respond to an Hg-induced autoimmune stimulus
with increased levels and altered quality of CIC compared with
mice expressing the intact receptors. The lack of increased IC
deposits in target organs for tissue IC deposits and the reduced
uptake of CIC in the liver speak in favour of a reduced elimination
of CIC but at the same time protection from a more pronounced
histological kidney damage.
Methods
Animals and housing
Female BALB/c mice with a targeted knockout mutation for the
signal-transducing (ITAM-containing) intracellular c-chain dimer
(FcRc
2/2), causing a functional loss of the activating FccRs, were
obtained from Taconic M&B (Georgetown, NY, USA). Corre-
sponding BALB/c mice without a mutation (wild type - wt mice)
were obtained from Taconic M&B (Ry, Denmark). All mice were
11–14 weeks old at onset of the experiments except for the animals
in the studies of blood clearance and tissue uptake of CIC, where
the mice were 39–44 weeks old. The mice were kept under specific
pathogen-free conditions and housed under 12-hour dark-/12-
hour light cycles in steel-wire cages. They were fed with pellets
(Transbreed E, Special Diets services, Witham, UK) and tap water
ad libitum. The animal ethics committee in Linko ¨ping approved the
study protocol (ID 14-06).
Treatment
Groups of wt and FcRc
2/2 mouse strains were exposed to
15 mg/L HgCl2 (Fluka Chemie, Buchs, Germany) in the sterilised
drinking water given ad libitum for 26–35 days. Control mice
received sterilised tap water only.
Blood and tissue sampling
Blood samples were obtained from the retro-orbital vein plexus.
The first groups of wt and FcRc
2/2 mice were bled before
onset of treatment and then after 12, 18, 26, and 35 days. At
sacrifice after 35 days treatment samples of the kidney and spleen
were obtained for examination of tissue IC deposits. The blood
was allowed to clot at 4uC for 2 hours, and CIC measured using
these fresh sera.
The second groups of wt and FcRc
2/2 mice were treated with
Hg for 12–35 days in order to assess the specific time needed for
formation of tissue IC deposit. Pieces of the kidney and spleen
were collected at sacrifice after 12, 14, 16, 18, 26, and 35 days of
treatment in wt mice, and after 12, 18, and 26 days of treatment in
FcRc
2/2 mice.
The third group of wt and FcRc
2/2 mice were treated with Hg
for 15–17 days and then given a single tail vein injection of 0.2 ml
preformed isotope-labelled soluble ICs (see below) at concentra-
tion of 0.7 mg/ml to analyse blood clearance and liver uptake of
CIC. Blood samples (50 ml) were taken after 0, 2, 4, 6, 8, 12, 22
and 32 minutes following the injection and the liver was collected
at sacrifice.
Assessment of circulating immune complexes
Circulating immune complexes assessed by PEG
precipitation followed by analyses of IgG1, IgG2a and
IgG2b ELISA. CIC in serum was measured by polyethylene
glycol (PEG)-induced precipitation of immune complexes [12,50].
Equal volumes of serum and 8% PEG (Fluka) were incubated at
4uC for 1 h and then centrifuged at 1000 g for 1 h. The pellet was
washed, resuspended in phosphate-buffered saline (PBS pH 7.4)
and stored at 220uC. The method used for detection of IgG1 has
been described before [27]. A standard curve using mouse
myeloma protein of the IgG1 (LO-IMEX) isotype was used to
obtain the actual concentration. The IgG2a and IgG2b content
were measured by a commercially available enzyme-linked
immunosorbent (ELISA) kit (Bethyl Laboratories Inc,
Montgomery, Texas, USA). To obtain the actual IgG2a or
IgG2b concentration the standard supplied with the kit was used.
Circulating immune complexes assessed by a C1q-
binding assay. CIC containing C1q were measured using a
mouse specific ELISA kit from Alpha Diagnostic International
(San Antonio, TX, USA). Briefly, serum was added to wells pre-
coated with C1q. A horseradish-peroxidise- (HRP-) conjugated
anti-mouse IgG detection antibody (ab) was added followed by
substrate buffer. After adding stop solution the absorbance was
measured at 450 nm and background values were subtracted.
Positive and negative controls included in the kit gave the expected
results.
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Pieces of the left kidney and the spleen were examined for IC
deposits with direct immunofluorescence microscopy as described
before [27]. Briefly, snap frozen tissue pieces were sectioned and
incubated with either a fluorescein-isothiocyanate- (FITC-)
conjugated goat anti-mouse ab against the IgG1, IgG2a, IgG2b
or IgG3 isotype (Southern Biotechnology, Birmingham, AL,
USA), C1q (Cedarlane, Burlington, Canada), or C3c (Organon-
Technica, West Chester, PA, USA). Kidneys from aged NZB/
WF1 mice were used as a positive control. The presence of
deposits in glomeruli, renal and splenic vessel walls was examined
with a fluorescence microscope (Nikon, Tokyo, Japan). The
endpoint titre for the IgG isotypes, C1q and C3c was defined as
the highest dilution of detection ab giving a specific staining of the
tissue. No staining at an ab dilution of 1:40 was considered as
negative and given the value 0. The amount of the IgG isotypes,
C1q and C3c in renal and splenic vessel walls was scored from 0–4
(0, no specific staining; 1, slight staining; 2, moderate staining; 3,
strong staining and 4, very strong staining). All examinations were
done without knowledge of treatment given or other results.
Immune complex formation and isotope labeling
DNP-conjugated HSA was prepared essentially as described
previously [51]. Briefly,1 g of HSA (Sigma, St Louis, Missouri,
USA) and 1 g potassium carbonate was dissolved in distilled water
and allowed to react with 1 g 2,4-dinitrobenzene sulfonate in the
dark, at 37uC under continuous agitation, for approximately 5 h
to achieve DNP-HSA with a conjugation degree of 4–6 DNP per
HSA. The DNP-HSA protein was then passed through a
Sephadex G-10 column and dialysed against distilled water at
4uC for 24 h, lyophilized and stored at 4uC.
125I-TC labelling and CIC formation
The radioactive tyramine cellbiose (TC) label has the advantage
of remaining intracellularly over a long time after endocytosis and
degradation, allowing analysis of accumulated intracellular uptake
of labelled IC. Radiolabelling of HSA was accomplished by the
TC method as previously described [52] with some modifications.
In brief, iodinated TC (
125I-TC) was prepared by reacting TC
(6 ml of 10 mM solution in PBS) with Na
125I (1.2 mCi, Perkin-
Elmer) in Iodo-Gen tubes (Pierce) for 30 min at room temperature
and was then activated by transferring the solution to a tube
containing cyanuric chloride (6 ml of 1.8 mg solution in acetone)
and potassium iodide (6 ml of 0.1 M solution) for 3 min. The
activated
125I-TC adduct was then covalently coupled to DNP-
HSA (0.5 mg in 200 ml 10 mM borate buffer, pH 8.8). To remove
unincorporated
125I-TC, the labelled protein (
125I-TC-DNP-HSA)
was passed through a Sephadex G-10 column (GE Healthcare)
eluated with PBS. Radiolabelled preparations were.95% tri-
chloroaetic acid-precipitable. Specific activities obtained were in
the range of 7–8610
5 cpm/mg. The
125I-TC moiety formed after
degradation of
125I-TC-labeled proteins is not released to the
medium but remains trapped in degradative compartments [52],
thus enabling assessment of the accumulated uptake of radioactive
protein over time.
125I-TC-labelled DNP-HSA was diluted with
PBS and allowed to react with polyclonal rabbit IgG anti-DNP ab
(AbD Serotec, Oxford, England) at 4-fold ab excess for 45 min at
37uC.
Statistical methods
Differences between the groups were analysed by the non-
parametric Mann-Whitney test or Fisher’s exact test. P,0.05 was
considered statistically significant.
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